ArticleEcancermedicalscience2017
Low-value practices in oncology contributing to financial toxicity.
Article in Ecancermedicalscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Article
- Financial toxicity in cancer palliative care in India: Addressing existence and beyond - Seeking remedies for a balanced financial journey.Ecancermedicalscience · 2024Article
- The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China.Frontiers in pharmacology · 2024Article
- Editorial: Hepatocellular carcinoma: from personalized medicine to practical guidelines.Frontiers in pharmacology · 2023Article
- Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments.Current oncology (Toronto, Ont.) · 2022Review
- Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis.Advances in therapy · 2022Article
- Low-value care and excess out-of-pocket expenditure among older adults with incident cancer - A machine learning approach.Journal of cancer policy · 2021Article
- The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009-2018.BMC cancer · 2021Article
- Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials.EClinicalMedicine · 2020Article
- Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions.EClinicalMedicine · 2020Article
- Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.Drugs · 2020Review
- Estimating the Direct Cost of Cancer in Nepal: A Cross-Sectional Study in a Tertiary Cancer Hospital.Frontiers in public health · 2019Article
- Does the oncology community have a rejection bias when it comes to repurposed drugs?Ecancermedicalscience · 2018Article
- A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study.Ecancermedicalscience · 2018Article
- Cancer treatment in the last 6 months of life: when inaction can outperform action.Ecancermedicalscience · 2018Article
- Cancer drugs in LMICs: cheap but unaffordable.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Financial toxicity of cancer treatment is now a well-recognised problem in cancer medicine leading to patient bankruptcy and even poor survival, including in high-income countries and countries with public health care systems. Many oncologists, despite acknowledging the severity of financial toxicity as a problem, resign the responsibility of reducing the costs of cancer treatment to the government, industry, and oncology societies. However, an oncologist can play an important role in reducing the costs of cancer treatment because all cancer treatment decisions are made between the oncologist and the patient. In this article, I point out a few examples of low value practices from various oncology disciplines that we oncologists can easily replace or abandon in our practice and contribute to lessening the financial toxicities to patients and society. As these examples suggest, reducing cost does not necessarily mean compromising efficacy. We should continuously keep looking for other similar cost-saving strategies in our practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.